CVS Health任命David Joyner为总裁兼首席执行官, 于10月17日生效, 取代Karen Lynch。 CVS Health appoints David Joyner as President and CEO, effective October 17, replacing Karen Lynch.

CVS Health已任命David Joyner为新总裁兼CEO, 于10月17日生效, 取代Karen Lynch。 CVS Health has named David Joyner as its new President and CEO, effective October 17, replacing Karen Lynch. Joyner 在医疗保健领域拥有超过 37 年的经验，此前曾担任 CVS Caremark 的总裁。 Joyner, with over 37 years in healthcare, previously served as CVS Caremark's president. 他的任命正值挑战之际，包括股价下跌近 20% 和影响 Aetna 的医疗费用上涨。 His appointment comes amid challenges, including a nearly 20% drop in share prices and rising medical costs impacting Aetna. CVS预计2024年第三季度每股1.05美元至1.10美元的调整后收益,以及削减成本和重组费用的措施. CVS anticipates adjusted earnings of $1.05 to $1.10 per share for Q3 2024, along with cost-cutting measures and restructuring charges.